Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Viatris Rolls Out 3 Follow-On AGs for Norvasc, Cardenalin, Relpax
Viatris Pharmaceuticals Japan said on March 5 that authorized generic (AG) versions are now available for the hypertension treatments Norvasc (amlodipine) and Cardenalin (doxazosin mesilate) and the migraine drug Relpax (eletriptan). Amlodipine Tablets/OD Tablets “Pfizer”, Doxazosin Tablets “Pfizer”, and Eletriptan…
To read the full story
Related Article
- Follow-On AGs Gaining Ground with 10 Launches in 2 Years, More Expected amid Generic Quality Concerns
September 9, 2021
- More Drug Makers Launching “Follow-on AGs”; Norvasc, Metgluco AGs Listed in December
December 18, 2020
- Authorized Generics for Lyrica, ComPlavin, Memary Dry Syrup Now Available
December 14, 2020
- Lyrica Faces Generic Debuts in Japan amid Patent Row: December Listing
December 10, 2020
- 22 Firms Get Approval for Lyrica Generics towards December Listing, Pfizer AG Included
August 18, 2020
BUSINESS
- Espha to Reinvest AG Profits into New Biz after Reform; Xarelto AG Logs 19 Billion Yen
May 15, 2026
- Meiji Opposes French Fund’s Push to Review Pharma Spin-Off
May 15, 2026
- FRONTEO Opens AI Drug Discovery Lab, Pivots to Out-Licensing Model
May 15, 2026
- Inqovi-Venetoclax Combo Wins FDA Approval in AML: Taiho
May 15, 2026
- Chugai Files Gazyva for Idiopathic Nephrotic Syndrome in Japan
May 15, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…